Eupraxia Pharmaceuticals announces promising results for EP-104GI in eosinophilic esophagitis trial

Eupraxia Pharmaceuticals Inc., listed on both TSX and NASDAQ under the ticker EPRX, has revealed encouraging results from its ongoing Phase 1b/2a RESOLVE trial. The trial is evaluating EP-104GI, a new treatment for eosinophilic esophagitis (EoE), utilizing the company’s proprietary DiffuSphere technology.

Trial Results Show Efficacy and Safety

The latest data from the RESOLVE trial’s first and second cohorts have demonstrated good tolerability and potential efficacy extending up to 24 weeks, with minimal side effects. These outcomes align with Eupraxia’s commitment to addressing unmet medical needs through innovative drug delivery systems. Dr. James Helliwell, CEO of Eupraxia, expressed optimism about the results, which also included promising findings from the third cohort indicating improvements in patient-reported symptoms and histological outcomes at 12 weeks.

Detailed Findings from the RESOLVE Trial

The trial utilized a dose-escalation format with EP-104GI administered via injections directly into the esophagus. The initial cohorts received doses ranging from four 1 mg injections to eight 2.5 mg injections, showing reductions in Peak Eosinophil Counts and improvements in the Eosinophilic Esophagitis Histology Scoring System scores, which gauge the severity and extent of the disease.

Eupraxia Pharmaceuticals Reports Positive Data for EP-104GI in Eosinophilic Esophagitis Clinical Trial

About the RESOLVE Trial

The RESOLVE trial is a multicentre, open-label study designed to assess the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with active EoE. The study spans several cohorts with participants evaluated over a period of up to 24 weeks.

Background on Eosinophilic Esophagitis

EoE is a chronic immune/antigen-mediated disease characterized by eosinophil infiltration into the esophagus, leading to significant dietary restrictions and quality of life degradation. According to a report by Clearview, over 450,000 individuals in the U.S. are affected by EoE, a number that is on the rise according to the American Gastroenterological Association.

Analysis

The ongoing success of the RESOLVE trial could mark a significant step forward in the treatment of EoE, potentially reducing the disease’s impact on patients’ daily lives. Eupraxia’s innovative approach, leveraging their DiffuSphere technology, might offer a more effective and patient-friendly treatment option compared to current therapies. The continued exploration of this technology underscores the importance of targeted drug delivery systems in the field of gastroenterology and could set new standards for treating inflammatory-mediated diseases.